HBM Holdings (FRA:6XY) Other Current Receivables: €25.1 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6XY HBM Holdings Ltd FRA:6XY
64 GF Score
Price €1.33
GF Value €0.74
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is HBM Holdings Other Current Receivables?

HBM Holdings FRA:6XY 64 Other Current Receivables is €25.1 Mil as of Dec. 2025. GuruFocus rates FRA:6XY with a GF Score™ of 64/100 and a GF Value™ of €0.74 (Significantly Overvalued). The stock has 4 warning signs investors should review.

HBM Holdings's Other Current Receivables for the quarter that ended in Dec. 2025 was €25.1 Mil.

HBM Holdings's quarterly Other Current Receivables increased from Dec. 2024 (€16.27 Mil) to Jun. 2025 (€18.25 Mil) and increased from Jun. 2025 (€18.25 Mil) to Dec. 2025 (€25.05 Mil).

HBM Holdings's annual Other Current Receivables increased from Dec. 2023 (€10.98 Mil) to Dec. 2024 (€16.27 Mil) and increased from Dec. 2024 (€16.27 Mil) to Dec. 2025 (€25.05 Mil).

HBM Holdings Other Current Receivables Related Terms

HBM Holdings Other Current Receivables Historical Data

* Premium members only.

The historical data trend for HBM Holdings's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HBM Holdings Other Current Receivables Chart

HBM Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial 1.14 18.15 10.98 16.27 25.05

HBM Holdings Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.98 15.90 16.27 18.25 25.05
FRA:6XY
64GF Score
HBM Holdings Ltd FRA:6XY
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HBM Holdings Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €25.1 Mil mean?
HBM Holdings (FRA:6XY) has a Other Current Receivables of €25.1 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on HBM Holdings and its competitors.
Is HBM Holdings' Other Current Receivables too high?
HBM Holdings' current Other Current Receivables is €25.1 Mil. Overall, HBM Holdings has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HBM Holdings' Other Current Receivables compare to VRTX and REGN?
HBM Holdings' Other Current Receivables of €25.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on HBM Holdings and its competitors. HBM Holdings's current Other Current Receivables is €25.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HBM Holdings stock overvalued right now?
Based on GuruFocus' analysis, HBM Holdings (FRA:6XY) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.74, compared to a current price of €1.33 — trading 79.7% above its estimated fair value. The current Other Current Receivables is €25.1 Mil. HBM Holdings' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For HBM Holdings (FRA:6XY), the current Other Current Receivables is €25.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HBM Holdings (FRA:6XY) Overvalued in 2026?

Based on GuruFocus' analysis, HBM Holdings stock appears to be overvalued. The current stock price of €1.33 is trading 79.7% above its estimated GF Value™ of €0.74. GuruFocus considers HBM Holdings to be Significantly Overvalued.

Key valuation signals for FRA:6XY:

  • Other Current Receivables: €25.1 Mil
  • GF Value™: €0.74 vs. price of €1.33 (79.7% above fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the FRA:6XY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HBM Holdings Business Description

Other Exchanges 02142:Hong Kong
Address No. 388 Fenglin Road, 6th Floor, Tower B, Fenglin International Phase I, Xuhui District, Shanghai, CHN, 200032
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the Europe.
64GF Score

Get the complete analysis for FRA:6XY

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.33
Price
€0.74
GF Value